-
CNDA approves first PARP inhibitor Lipdro ® (Olapari tablet) for maintenance therapy for recurrent ovarian cancer
Time of Update: 2020-06-11
over the past 10 years, the incidence of ovarian cancer in China has increased by 30 per cent and the mortality rate by 18 per cent However, ovarian cancer had the lowest 5-year survival rate in gyn
-
Deqi Pharma's new class of drugs for the treatment of HCC, ATG-008, gets clinical approval
Time of Update: 2020-06-11
June 2018, Deqi Pharmaceutical (announced that the Company (developed for the treatment of advanced hepatocellular carcinoma (HCC) of a class of new drugs (through the National Medicines (Th
-
FDA approves its Cequa for treatment of dry corneal conjunctivitis
Time of Update: 2020-06-11
dry eye disease is one of the most common eye diseases, with an estimated 16 million U.S adults diagnosed with dry eye disease Dry eye disease is a multi-factor disease associated with the surface o
-
FDA grants orphan status for targeted drug tenagisib (RP6530) for skin T-cell lymphoma
Time of Update: 2020-06-11
recently, Rhizen Pharmaceutical son hasing ( FDA has granted the targeted drug tenagisib (RP6530) the status of an orphan drug for the treatment of skin T-cell lymphoma (CTCL) Prior to , the FDA
-
CHMP approves Briviact extended indications
Time of Update: 2020-06-11
recently, the Belgian Pharmaceutical (UCB) announced that the European Pharmaceutical (EMA) for human medicines ( CHMP) has issued a positive opinion recommending the approval of Briviact (br
-
FDA has awarded the first three co-discovery of the new drug quizartinib breakthrough therapy
Time of Update: 2020-06-11
AML is a malignant blood and bone marrow cancer that causes abnormally dysfunctional cancerous white blood cells in the patient's body to grow and accumulate uncontrolledly and affect the production
-
FDA announces approval of Omegaven
Time of Update: 2020-06-11
recently, the U.S FDA to approve Omegaven as a calorie and fatty acid supplement for children suffering from "intestinal nutrition-related bile siltation." Omegaven Omegaven is by Fresenius Kab
-
FDA accepts new drug listing for brexanolone (SAGE-547) intravenous injection syltorapy for postpartum depression
Time of Update: 2020-06-11
recently, Sage Therapeutics announced that FDA (which has accepted the of new drugs (NDA) for the treatment of postpartum depression with brexanolone (SAGE-547) intravenous injections, and grant
-
Pfizer and Merck release 2-year update on PD-L1 immunotherapy Bavencio
Time of Update: 2020-06-11
MCC is a rare invasive skin cancer, clinical prognosis is very poor, metastatic MCC mortality rate is higher than melanoma, 1 year survival rate is not more than 50%, 5 yearsurvival rate is not more
-
Zhifei bio five-price re-matching rotavirus detoxification live vaccine has been approved by the State Administration of Drug Supervision and Administration
Time of Update: 2020-06-11
recently, Chongqing Zhifei Biological Products Limited Company (announced that the company's five-price re-distribution rotavirus detoxifying live vaccine (Vero cells), the commodity name "Le Dele
-
FDA approves Oxervate developed by Domp? for treatment of neurotrophic keratitis
Time of Update: 2020-06-11
neurotrophic keratitis is a rare degenerative disease caused by loss of cornea sensation Loss of cornea sensation softens the cornea's surface, including thinning of the cornea, ulceration, and perf
-
Beijing Senoki Pharmaceuticals Co., Inc. variety SNG1153 approved for clinical trials in the U.S.
Time of Update: 2020-06-11
Recently, Beijing Shengnoki Pharmaceutical (Technology Limited Company (receiving notice from the U.S Food Medicines ( FDA ()), the company's variety SNG1153 is allowed to conduct clinical t
-
Reed ingress medicine ® has been approved in Hong Kong for the treatment of epithelial ovarian cancer patients
Time of Update: 2020-06-11
recently, the Pharmaceutical (NASDAQ: ZLAB) announced that the ® (ZEJULA ®, Niraparib) has been approved in Hong Kong for the treatment of patients with platinum-sensitive recurrent high-level slu
-
Psoriasis treatment drug Bryhali (halobetasol propionate) emulsion launched in US
Time of Update: 2020-06-11
recently, Bausch Health (and its dermatology company, Ortho Dermatologics) announced the launch of Bryhali (halobetasol propionate, 0.01%) emulsion in the United States, a local treatment drug (
-
Clinical trial of dry eye treatment drug reproxalap clinical 2b yields positive results
Time of Update: 2020-06-11
dry eye disease is a common inflammatory disease that affects about 20 million people in the United States The disease is characterized by inadequate moisture and lubrication on the front surface of
-
GlaxoSmithKline M72/AS01E candidate vaccine gets positive results in Phase 2b clinical trial
Time of Update: 2020-06-11
tuberculosis is one of the leading causes of infectious disease death worldwide It is estimated that one quarter of the world's population is infected with latent tuberculosis, in which case mycobact
-
Green leaf pharmaceutical injection with rothegotin retardation microsphere (LY03003) launches Phase III clinical trial in China
Time of Update: 2020-06-11
June 20, Green leaf Pharmaceutical (a notice) announced that the injection of rothegotin reprieve microsphere (LY03003) in China to launch phase III clinical trial () about LY 03003 LY 03003 is
-
New drug CM082 and JS001 jointclinical clinical trial application spree for melanoma has been accepted by the National Drug Administration
Time of Update: 2020-06-11
recently, , Beida Pharmaceuticals announced that the of the wholly-owned sub- company (Kananji Pharmaceutical (Shanghai) Co., Ltd received the National Pharmaceutical (The Notice of Acceptance o
-
Lilly Alimta and Merck Keytruda's drug combination therapy approved as a first-line treatment for NSCLC patients
Time of Update: 2020-06-11
recent days, U.S regulators have approved Lilly Alimta and Merck Keytruda's drug (combined therapy) as a first-line treatment for patients with metastatic non-small cell lung cancer (NSCLC) Lilly
-
CFDA approves Gilead propien sand ® for treatment of adult strains with chronic hepatitis C virus 1-6
Time of Update: 2020-06-11
Gilead Scientific Company (NASDAQ: GILD) announced that the National Drug (the Supervisory Authority approved the propane sand ® (Sophobuvir 400 mg / Vipatavir 100 mg) can be used to treat adult
